Literature DB >> 23913859

Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.

Mahefatiana Andrianifahanana1, Mark C Wilkes, Shiv K Gupta, Rod A Rahimi, Claire E Repellin, Maryanne Edens, Joshua Wittenberger, Xueqian Yin, Elizabeth Maidl, Jackson Becker, Edward B Leof.   

Abstract

Transforming growth factor β (TGFβ) has significant profibrotic activity both in vitro and in vivo. This reflects its capacity to stimulate fibrogenic mediators and induce the expression of other profibrotic cytokines such as platelet-derived growth factor (PDGF) and epidermal growth factor (EGF/ErbB) ligands. Here we address both the mechanisms by which TGFβ induced ErbB ligands and the physiological significance of inhibiting multiple TGFβ-regulated processes. The data document that ErbB ligand induction requires PDGF receptor (PDGFR) mediation and engages a positive autocrine/paracrine feedback loop via ErbB receptors. Whereas PDGFRs are essential for TGFβ-stimulated ErbB ligand up-regulation, TGFβ-specific signals are also required for ErbB receptor activation. Subsequent profibrotic responses are shown to involve the cooperative action of PDGF and ErbB signaling. Moreover, using a murine treatment model of bleomycin-induced pulmonary fibrosis we found that inhibition of TGFβ/PDGF and ErbB pathways with imatinib plus lapatinib, respectively, not only prevented myofibroblast gene expression to a greater extent than either drug alone, but also essentially stabilized gas exchange (oxygen saturation) as an overall measure of lung function. These observations provide important mechanistic insights into profibrotic TGFβ signaling and indicate that targeting multiple cytokines represents a possible strategy to ameliorate organ fibrosis dependent on TGFβ.

Entities:  

Keywords:  EGF; pulmonary fibrosis

Mesh:

Substances:

Year:  2013        PMID: 23913859      PMCID: PMC3804746          DOI: 10.1096/fj.12-224907

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  59 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads.

Authors:  L M Taylor; L M Khachigian
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

Review 3.  Growth factors and cancer.

Authors:  A S Goustin; E B Leof; G D Shipley; H L Moses
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

4.  Agents that increase cAMP accumulation block endothelial c-sis induction by thrombin and transforming growth factor-beta.

Authors:  T O Daniel; V C Gibbs; D F Milfay; L T Williams
Journal:  J Biol Chem       Date:  1987-09-05       Impact factor: 5.157

5.  Gefitinib prevents bleomycin-induced lung fibrosis in mice.

Authors:  Yoshiki Ishii; Sakae Fujimoto; Takeshi Fukuda
Journal:  Am J Respir Crit Care Med       Date:  2006-06-01       Impact factor: 21.405

6.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

7.  CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC.

Authors:  Youjun Chen; Ingrid E Blom; Susan Sa; Roel Goldschmeding; David J Abraham; Andrew Leask
Journal:  Kidney Int       Date:  2002-10       Impact factor: 10.612

8.  Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta.

Authors:  Rod A Rahimi; Mahefatiana Andrianifahanana; Mark C Wilkes; Maryanne Edens; Theodore J Kottom; John Blenis; Edward B Leof
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

9.  The pathogenesis of bleomycin-induced pulmonary fibrosis in mice.

Authors:  I Y Adamson; D H Bowden
Journal:  Am J Pathol       Date:  1974-11       Impact factor: 4.307

10.  Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis.

Authors:  Alfiya Akhmetshina; Katrin Palumbo; Clara Dees; Christina Bergmann; Paulius Venalis; Pawel Zerr; Angelika Horn; Trayana Kireva; Christian Beyer; Jochen Zwerina; Holm Schneider; Anika Sadowski; Marc-Oliver Riener; Ormond A MacDougald; Oliver Distler; Georg Schett; Jörg H W Distler
Journal:  Nat Commun       Date:  2012-03-13       Impact factor: 14.919

View more
  25 in total

1.  Inhibition of the αvβ6 integrin leads to limited alteration of TGF-α-induced pulmonary fibrosis.

Authors:  Satish K Madala; Thomas R Korfhagen; Stephanie Schmidt; Cynthia Davidson; Ramakrishna Edukulla; Machiko Ikegami; Shelia M Violette; Paul H Weinreb; Dean Sheppard; William D Hardie
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-02-07       Impact factor: 5.464

Review 2.  Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease.

Authors:  Helena M Kok; Lucas L Falke; Roel Goldschmeding; Tri Q Nguyen
Journal:  Nat Rev Nephrol       Date:  2014-10-14       Impact factor: 28.314

3.  Profibrotic up-regulation of glucose transporter 1 by TGF-β involves activation of MEK and mammalian target of rapamycin complex 2 pathways.

Authors:  Mahefatiana Andrianifahanana; Danielle M Hernandez; Xueqian Yin; Jeong-Han Kang; Mi-Yeon Jung; Youli Wang; Eunhee S Yi; Anja C Roden; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2016-08-01       Impact factor: 5.191

4.  Cell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-β signaling.

Authors:  Jeong-Han Kang; Mi-Yeon Jung; Xueqian Yin; Mahefatiana Andrianifahanana; Danielle M Hernandez; Edward B Leof
Journal:  J Clin Invest       Date:  2017-05-22       Impact factor: 14.808

Review 5.  Blocking fibrotic signaling in fibroblasts from patients with carpal tunnel syndrome.

Authors:  Yoshiaki Yamanaka; Anne Gingery; Gosuke Oki; Tai-Hua Yang; Chunfeng Zhao; Peter C Amadio
Journal:  J Cell Physiol       Date:  2017-05-03       Impact factor: 6.384

6.  Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.

Authors:  Hongmei Gu; Amanda J Fisher; Elizabeth A Mickler; Frank Duerson; Oscar W Cummings; Marc Peters-Golden; Homer L Twigg; Trent M Woodruff; David S Wilkes; Ragini Vittal
Journal:  FASEB J       Date:  2016-03-08       Impact factor: 5.191

7.  IPF pathogenesis is dependent upon TGFβ induction of IGF-1.

Authors:  Danielle M Hernandez; Jeong-Han Kang; Malay Choudhury; Mahefatiana Andrianifahanana; Xueqian Yin; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

8.  Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion.

Authors:  Rudolf K Braun; Jill M Koch; Timothy A Hacker; David Pegelow; Jaehyup Kim; Amish N Raval; Eric G Schmuck; Denise J Schwahn; Derek J Hei; John M Centanni; Marlowe Eldridge; Peiman Hematti
Journal:  Cytotherapy       Date:  2016-04       Impact factor: 5.414

9.  Transforming growth factor β and platelet-derived growth factor modulation of myofibroblast development from corneal fibroblasts in vitro.

Authors:  Vivek Singh; Flavia L Barbosa; Andre A M Torricelli; Marcony R Santhiago; Steven E Wilson
Journal:  Exp Eye Res       Date:  2014-01-12       Impact factor: 3.467

10.  Identification of differentially expressed genes and signaling pathways using bioinformatics in interstitial lung disease due to tyrosine kinase inhibitors targeting the epidermal growth factor receptor.

Authors:  Yuan Lu; Ang Li; Xiaofeng Lai; Jun Jiang; Lihong Zhang; Zhicheng Zhong; Wen Zhao; Ping Tang; Hu Zhao; Xinling Ren
Journal:  Invest New Drugs       Date:  2018-09-10       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.